RedHill Biopharma Ltd – ADR (RDHL) is Reiterated by FBR Capital to Outperform, Raises Price Target to $ 36

RedHill Biopharma Ltd – ADR (RDHL) was Reiterated by FBR Capital to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 36 from a previous price target of $33 . FBR Capital advised their investors in a research report released on Jul 27, 2016.

RedHill Biopharma Ltd – ADR opened for trading at $12.4 and hit $12.7 on the upside on Thursday, eventually ending the session at $12.7, with a gain of 2.42% or 0.3 points. The heightened volatility saw the trading volume jump to 26,525 shares. Company has a market cap of $161 M.

RedHill Biopharma Ltd. is a biopharmaceutical company primarily focused on the development of late clinical-stage orally-administered small molecule drugs for the treatment of inflammatory and gastrointestinal diseases including gastrointestinal cancers. The Company’s pipeline of products includes RHB-105 RHB-104 BEKINDA (RHB-102) RHB-106 ABC294640 MESUPRON RP101 and RIZAPORT (RHB-103).

RedHill Biopharma Ltd - ADR

Leave a Reply

RedHill Biopharma Ltd - ADR - Is it time to Sell?

Top Brokerage Firms are advising their investors on RedHill Biopharma Ltd - ADR. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.